Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sadick Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$1,255,753

162 payments

Through program year 2025, Sadick Research Group LLC is reported as receiving $1,255,753 in research payments, across 162 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $209,367 29
2024 Research $61,572 9
2023 Research $181,073 11
2022 Research $249,152 20
2021 Research $125,324 17
2020 Research $72,442 18
2019 Research $356,823 58

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $384,821 30 payments
  2. Bausch Health US, LLC $355,086 36 payments
  3. LEO Pharma AS $113,398 33 payments
  4. Sanofi US Services Inc. $103,223 11 payments
  5. Aclaris Therapeutics, Inc. $73,627 16 payments
  6. Janssen Research & Development, LLC $71,300 9 payments
  7. Pfizer Inc. $60,746 5 payments
  8. AbbVie, Inc. $36,844 6 payments
  9. Almirall LLC $17,800 2 payments
  10. Vanda Pharmaceuticals Inc. $17,393 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $102,657 2 payments
  2. An open-label, single-center, prospective, observational, clinical use study evaluating the safety and efficacy of Arazlo (tazarotene lotion) applied once daily for the treatment of melasma and facial inflammatory pigmentation $94,080 6 payments
  3. A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of Idp-126 Gel to Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris $86,521 8 payments
  4. An open-label, single-center, prospective, observational, clinical use study evaluating the safety and efficacy of ARAZLO (tazarotene lotion) applied once daily for the treatment of wrinkles, fine lines, and photoaging $78,210 5 payments
  5. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $71,300 9 payments
  6. Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study $54,520 10 payments
  7. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $51,987 5 payments
  8. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Ati-501 Oral Suspension Compared to Placebo in Adult Subjects With Alopecia Areata, Alopecia Universalis Or Alopecia Totalis $49,475 8 payments
  9. Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $49,371 3 payments
  10. Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend $49,046 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record